Kymera Therapeutics, Inc. (KYMR) earnings date
Feb 25, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 11 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Oct 29, 2026 | before open | 29 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Thu, Apr 30, 2026 | before open | 30 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | before open | 35 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | before open | 42 | 8-K |
| Q1 FY2025 | Fri, May 9, 2025 | before open | 39 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027 Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data to be reported by year-end 2026 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected" exhibit |
| Q3 FY2026 | "Subject to discussions with regulators, the Company expects to initiate the first Phase 3 trial in AD by mid-2027." exhibit |
| Q3 FY2026 | "Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027." exhibit |
| Q3 FY2026 | "The Company does not expect to recognize additional collaboration revenue in 2026." exhibit |
| Q3 FY2026 | "Kymera expects that its cash balance will provide the Company with a cash runway into 2029 beyond multiple clinical inflection points in its pipeline." exhibit |
| Q2 FY2026 | "Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26" exhibit |
| Q2 FY2026 | "The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options.”" exhibit |
| Q2 FY2026 | "The earlier than expected completion of enrollment enabled the Company to accelerate its expected topline data readout by six months to year-end 2026, earlier than prior guidance to share data by mid-2027." exhibit |
| Q2 FY2026 | "Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027." exhibit |
| Q2 FY2026 | "The Company expects to report data in late 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KYMR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KYMR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/KYMR/"><img src="https://veritasdata.dev/embed/KYMR.svg" alt="KYMR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/KYMR/)
Script
<script async src="https://veritasdata.dev/embed/KYMR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KYMR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.